Cargando…

Carboplatin-Pemetrexed in Treatment of Patients with Recurrent/Metastatic Cancers of the Head and Neck; Superior Outcomes in Oropharyngeal Primaries

Background: Platinum-based therapy in combination with 5-fluorouracil with cetuximab has shown the best survival in pts with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The purpose of this study is to evaluate the efficacy and tolerability of carboplatin, pemetrexe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malhotra, Binu, Bellile, Emily Light, Nguyen, Nghia Pham Trung, Fung, Vicki Kay, Slack, Matthew, Bilich, Rebecca, Papagerakis, Silvana, Worden, Francis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306299/ https://www.ncbi.nlm.nih.gov/pubmed/25674535 http://dx.doi.org/10.3389/fonc.2014.00362

Ejemplares similares

Carboplatin/pemetrexed: COVID-19 infection: 2 case reports
Publicado: (2021)

Carboplatin/pembrolizumab/pemetrexed: COVID-19 pneumonia: case report
Publicado: (2021)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Sinus arrhythmia caused by pemetrexed with carboplatin combination: A case report
por: Quan, Xianghua, et al.
Publicado: (2022)

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
por: Zhu, Yixiang, et al.
Publicado: (2018)

Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin
por: Eichhoff, Gerhard
Publicado: (2020)

Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy
por: Roskies, M., et al.
Publicado: (2016)

Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report
por: Sato, Takashi, et al.
Publicado: (2012)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
por: Hayashi, Toshinobu, et al.
Publicado: (2021)

Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer
por: Kim, Yi Rang, et al.
Publicado: (2018)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Zinner, Ralph G., et al.
Publicado: (2015)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette, Wolfgang, et al.
Publicado: (2017)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
por: Ceresoli, G L, et al.
Publicado: (2008)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
por: Zhang, Guan-Zhong, et al.
Publicado: (2010)

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
por: Blais, Normand, et al.
Publicado: (2013)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
por: Shen, Xinglei, et al.
Publicado: (2011)

Acute cerebral arterial embolism following pemetrexed and carboplatin treatment in non-small-cell lung cancer: A case report
por: TAKEDA, MASAYUKI, et al.
Publicado: (2013)

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer
por: Brooks, Gabriel A., et al.
Publicado: (2018)

Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report
por: Kawakado, Keita, et al.
Publicado: (2021)

Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
por: Pereira, José Rodrigues, et al.
Publicado: (2013)

Selective digestive decontamination is superior to selective oropharyngeal decontamination
por: Silvestri, Luciano, et al.
Publicado: (2011)

Systems Biology Approaches and Precision Oral Health: A Circadian Clock Perspective
por: Adeola, Henry A., et al.
Publicado: (2019)

The role of human papillomavirus in the pathogenesis of head & neck squamous cell carcinoma: an overview
por: Pannone, Giuseppe, et al.
Publicado: (2011)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Calcium Sets the Clock in Ameloblasts
por: Said, Raed, et al.
Publicado: (2020)

Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells
por: Desiderio, Vincenzo, et al.
Publicado: (2014)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

Carboplatin binding to histidine
por: Tanley, Simon W. M., et al.
Publicado: (2014)

Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study
por: Kawazoe, Hitoshi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qlubqf2jm453o82k35fcrghqdr